Biopsy Devices Market - Consumption, Export, Import by Regions, Competitors, Pricing Strategy, Brand Strategy


Posted April 1, 2019 by sunny88

Biopsy Devices Market was valued at $1,621 million, and is expected to reach $2,399 million by 2022, supported by a CAGR of 5.8%.

 
Biopsy is the surgical removal of tissue from an organ to determine the presence or extent of a disease, mostly cancerous and inflammatory conditions. This diagnostic procedure is generally performed by surgeons, radiologists, and interventional cardiologists, to confirm the presence of cancerous tissue.

Biopsy procedures can be performed for almost any organ with the help of a specific biopsy device. Conventional biopsy devices can be complemented with advanced imaging technologies such as MRI-guided biopsy, stereotactic-guided biopsy, ultrasound-guided biopsy, CT scan, and others to perform a biopsy procedure with accuracy and minimal invasiveness. These integrated procedures are important to perform biopsies in critical areas of the body such as the lungs, liver, and kidney.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/1424

The key companies profiled in the report are
• C.R. Bard Inc.
• Leica Biosystems
• Hologic Inc.
• Becton
• Dickinson and Company
• Ethicon EndoSurgery Inc.
• Fujifilm Medical Systems
• Veran Medical Technologies
• Boston Scientific Corporation
• MDxHealth
• Mauna Kea Technologies
• Cook Medical Inc.
• Medtronic
• Argon Medical Devices Inc
• Intact Medical Corp.

North America was the highest revenue generating region due to rise in incidences of chronic diseases in 2015. North America and Europe, collectively, accounted for more than three-fourths of the overall market in 2015; this trend is likely to continue over the forecast period. Factors that drive the growth of biopsy devices in the developed regions are awareness about cancer diagnosis, high purchasing power, and availability of skilled personnel to perform biopsy procedures.

Make a Request for Customization @ https://www.alliedmarketresearch.com/request-for-customization/1424

Key Findings of Biopsy Devices Market:
• CT-guided biopsy segment is anticipated to grow at the highest CAGR of 6.3% during the forecast period.
• The diagnostic centers would continue to lead the revenue generating end use segment by garnering around half of the share in the overall market.
• Lung biopsy is projected to be the fastest growing application segment, registering a CAGR of 7.0%.
• The robotic guidance system segment is expected to register the highest CAGR of 7.0%.
• The Asia-Pacific region is projected to be the fastest growing market, with a CAGR of 7.2%.
• Hospitals are projected be the fastest growing end use segment, owing to increase in integration of diagnostic facilities within the premises.
.
Access Full Summery @ https://www.alliedmarketresearch.com/biopsy-devices-market
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Allied Market Research
Business Address 5933 NE Win Sivers Drive, #205, Portland, OR 97220, United States. Int'l: +1-503-894-6022 Toll Free: +1-800-792-5285 Fax: +1-800-792-5285 [email protected]
Country United States
Categories Industry , Medical , Research
Last Updated April 1, 2019